JOP20170044B1 - تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو - Google Patents

تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو

Info

Publication number
JOP20170044B1
JOP20170044B1 JOP/2017/0044A JOP20170044A JOP20170044B1 JO P20170044 B1 JOP20170044 B1 JO P20170044B1 JO P20170044 A JOP20170044 A JO P20170044A JO P20170044 B1 JOP20170044 B1 JO P20170044B1
Authority
JO
Jordan
Prior art keywords
growth hormone
hormone deficiency
patient
pharmaceutical composition
dosage
Prior art date
Application number
JOP/2017/0044A
Other languages
English (en)
Inventor
Ji-Eun Cha
Joan Yoon Ji Lee
Woo Ick Jang
Kyung Kim Tae
Jung Won Woo
Young Joo Ahn
Original Assignee
Genexine Inc
Handok Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genexine Inc, Handok Inc filed Critical Genexine Inc
Application granted granted Critical
Publication of JOP20170044B1 publication Critical patent/JOP20170044B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

يتعلق الكشف الحالي بطريقة إعطاء هرمون نمو بشري ناتج عن إعادة الارتباط الجيني GX-H9 لعلاج نقص هرمون النمو. وبالتحديد، يتعلق الكشف الحالي بتركيبة صيدلانية لعلاج نقص هرمون النمو، تتضمن هرمون النمو البشري hGH GX-H9 ناتج عن إعادة الارتباط الجيني ومادة حاملة مقبولة صيدلانيا، وفيها يتم إعطاء GX-H9 الناتج عن إعادة الارتباط الجيني مرة واحدة أسبوعيا بجرعة تتراوح من 0.1 الى 0.3 مجم لكل كجم من وزن مريض أو مرتين شهريا بجرعة تتراوح من 0.1 الى 0.4 مجم لكل كجم من وزن مريض. علاوة على ذلك، يتعلق الاختراع الحالي بطريقة علاج نقص هرمون النمو تتضمن إعطاء هرمون النمو البشريandnbsp; hGH GX-H9 الناتج عن إعادة الارتباط الجيني لمريض يعاني من نقص هرمون النمو مرة واحدة أسبوعيا بجرعة تتراوح من 0.1 الى 0.3 مجم لكل كجم من وزن المريض أو مرتين شهريا بجرعة تتراوح من 0.1 الى 0.4 مجم لكل كجم من وزن المريض
JOP/2017/0044A 2016-02-17 2017-02-16 تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو JOP20170044B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20160018695 2016-02-17

Publications (1)

Publication Number Publication Date
JOP20170044B1 true JOP20170044B1 (ar) 2021-08-17

Family

ID=59761652

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2017/0044A JOP20170044B1 (ar) 2016-02-17 2017-02-16 تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو

Country Status (14)

Country Link
US (1) US12233113B2 (ar)
EP (1) EP3416677B1 (ar)
JP (1) JP6896749B2 (ar)
KR (2) KR20170096968A (ar)
CN (1) CN109152816B (ar)
CA (1) CA3014164A1 (ar)
DK (1) DK3416677T3 (ar)
ES (1) ES2925901T3 (ar)
HU (1) HUE059593T2 (ar)
JO (1) JOP20170044B1 (ar)
PL (1) PL3416677T3 (ar)
PT (1) PT3416677T (ar)
RU (1) RU2732113C2 (ar)
TW (1) TWI748990B (ar)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118105512A (zh) 2016-08-30 2024-05-31 株式会社吉耐森 含有hGH融合蛋白的治疗生长激素缺乏症的药物组合物
CN114874333B (zh) * 2021-10-18 2025-01-24 深圳科兴药业有限公司 一种生长激素融合蛋白及其应用
MX2024006318A (es) 2021-11-26 2024-08-14 Genexine Inc Formulacion para administracion de alta concentracion de proteina de fusion de hormona del crecimiento.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
EP2059260B1 (en) 2006-08-31 2013-06-19 Novartis AG Pharmaceutical compositions comprising hGH for oral delivery
CN101687933B (zh) 2007-05-30 2015-11-25 浦项工科大学校产学协力团 免疫球蛋白融合蛋白
KR101333958B1 (ko) 2010-10-20 2013-11-27 주식회사 한독 인간 인터루킨-1 수용체 길항제-하이브리드 Ｆｃ 융합단백질
CN102875683B (zh) * 2011-07-11 2014-06-11 旭华（上海）生物研发中心有限公司 长效重组人生长激素的Fc融合蛋白
CN107320719A (zh) 2012-06-05 2017-11-07 阿穆尼克斯运营公司 Hgh‑xten融合蛋白及其在治疗生长激素缺乏中的用途
WO2014164568A1 (en) * 2013-03-11 2014-10-09 Amunix Operating Inc. Treatment of pediatric growth hormone deficiency with human growth hormone analogues
US20160015789A1 (en) 2014-07-17 2016-01-21 Teva Pharmaceutical Industries, Ltd. FORMULATIONS OF AN ALBUMIN hGH FUSION PROTEIN
EP4732848A3 (en) 2014-11-21 2026-07-29 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms
WO2018044060A1 (en) 2016-08-30 2018-03-08 Genexine,Inc. PHARMACEUTICAL COMPOSITION FOR TREATING GROWTH HORMONE DEFICIENCY CONTAINING hGH FUSION PROTEIN
CN118105512A (zh) 2016-08-30 2024-05-31 株式会社吉耐森 含有hGH融合蛋白的治疗生长激素缺乏症的药物组合物

Also Published As

Publication number Publication date
RU2018132694A3 (ar) 2020-03-17
US20210177945A1 (en) 2021-06-17
CA3014164A1 (en) 2017-08-24
CN109152816B (zh) 2022-08-16
JP2019508421A (ja) 2019-03-28
RU2018132694A (ru) 2020-03-17
TW201729831A (zh) 2017-09-01
ES2925901T3 (es) 2022-10-20
PL3416677T3 (pl) 2022-11-21
US12233113B2 (en) 2025-02-25
JP6896749B2 (ja) 2021-06-30
BR112018016817A2 (pt) 2018-12-26
PT3416677T (pt) 2022-09-06
KR102312986B1 (ko) 2021-10-14
KR20170096968A (ko) 2017-08-25
CN109152816A (zh) 2019-01-04
DK3416677T3 (da) 2022-08-29
EP3416677A1 (en) 2018-12-26
HUE059593T2 (hu) 2022-12-28
EP3416677A4 (en) 2019-11-06
TWI748990B (zh) 2021-12-11
KR20180135839A (ko) 2018-12-21
EP3416677B1 (en) 2022-08-03
RU2732113C2 (ru) 2020-09-11

Similar Documents

Publication Publication Date Title
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MY199903A (en) Combination therapy with controlled-release cnp agonists
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
RU2014102924A (ru) Композиция для контролируемой стимуляции яичников
MY204827A (en) Semaglutide in medical therapy
PH12018550210A1 (en) Oral dosage form with drug composition, barrier layer and drug layer
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
RU2017120184A (ru) Лекарства для замедления течения болезни паркинсона
JOP20190019B1 (ar) تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH)
NZ617397A (en) Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units
MX2023011203A (es) Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular.
ZA202000028B (en) Use of vibegron to treat overactive bladder
PH12015502465A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
MX2013003523A (es) Composicion farmaceutica de dosis baja.
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
MY193963A (en) Composition for treating joint diseases and kit containing same
NZ751972A (en) Treatment of prurigo nodularis
MX2018005876A (es) Regimen de dosificacion de plasminogeno para la cicatrizacion de heridas.
WO2012044783A3 (en) Method of achieving a thymosin beta 4 concentration in a human patient
RU2018132694A (ru) Фармацевтическая композиция, включающая рекомбинантный гормон роста человека для лечения дефицита гормона роста
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
MX2023005695A (es) Administracion de agonista de sting, inhibidores de puntos de control y radiacion.
JP2018522881A5 (ar)
MX2012005497A (es) Tivozanib y temsirolimus en combinacion.